Linking Oncology Diagnostic Labs to Assess their Effectiveness in Supporting Immunotherapy Treatment Selection in Lung Cancer

A molecular diagnostics company developed a blood test intended to help select treatment for patients with advanced non-small cell lung cancer (NSCLC), addressing the fact that many EGFR-mutated, PD-L1-expressing NSCLC patients do not respond to immune checkpoint inhibitors. The page states the need for "a more precise test to determine which patients with this tumor type would respond to ICIs," and frames the company's blood test as targeting that gap using linked oncology diagnostic lab data via Datavant. The page names partner organizations (Quest Diagnostics, Avandra, Trio Health, among others) but does not provide specific outcome metrics or results.

The customer is anonymised in Datavant’s own case study — not withheld by us.

Datavant is the tokenization and linkage infrastructure behind most of the US real-world-data ecosystem — it de-identifies and connects patient records across health-data partners without exposing PII.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.